Arphra/Issuer/IDXX

IDXX

IDEXX Laboratories, Inc.

HealthcareMedical - Diagnostics & ResearchUSUSD

$555.44

-1.22%LiveJun 01, 2026

AI Brief

Market cap

$43.81B

52w range

504.56 – 769.98

P / E

—

EPS

—

Volume

60.89K

Revenue · FY

$4.3B

+10.42% YoY

Explain this page

Arphra AIPlain-English read on IDEXX Laboratories, Inc.’s valuation

AI Issuer Brief

Arphra AI

Loading cached brief…

Insider · 30d

Bought

0 txns

Sold

$8.56M

10 txns

Net flow

−$8.56M

Full history →

Price

DB · prices_daily

1M 6M 1Y 5Y

Last

$557.63

Change

+8.32%

Period high

$766.68

Period low

$514.61

Period start

$514.802025-06-02

Through 2026-05-04

Peers

Price change · trailing returns

Live

1D	5D	1M	3M	6M	YTD	1Y	3Y	5Y	10Y	Max
-1.44%	-0.02%	-2.12%	-15.42%	-23.80%	-17.90%	+7.89%	+18.22%	+0.88%	+529.89%	+117413.90%

Aftermarket

Live

Jun 01, 02:29 PM

Last trade

$555.44

7 sh

Bid

$553.22

40 sh

Ask

$556.16

20 sh

Spread

$2.940

Sector & industry today

Live

Sectors

Technology
+2.44%
Energy
+1.31%
Consumer Cyclical
+0.18%
Real Estate
-0.27%
Industrials
-0.28%
Financial Services
-0.30%
Consumer Defensive
-0.46%
Healthcare
-0.70%
Basic Materials
-1.03%
Utilities
-1.10%
Communication Services
-1.25%

Top industries (issuer's industry highlighted)

Medical - Diagnostics & Research
-0.43%
Integrated Freight & Logistics
-12.58%
Information Technology Services
+8.89%
Computer Hardware
+5.74%
Coal
+4.42%
Software - Application
+2.70%
Electronic Gaming & Multimedia
-2.49%
Luxury Goods
-1.97%
Industrial - Pollution & Treatment Controls
-1.89%
Gambling, Resorts & Casinos
+1.88%
Communication Equipment
+1.80%
Agricultural Inputs
-1.65%

Fair value

Football field →

Weighted blend

$323.42

-41.77% vs spot

Recommendation

Sell

15 of 16 methods

Method spread

1bull13bear

±5% threshold

Analyst PT consensus: $773.13 (+39.19%)

Total assets

$3.35B

Total debt

$1.08B

Cash & equiv

$180.07M

Operating CF

$1.18B

Free cash flow

$1.05B

Buybacks

-$1.22B

Analyst view

DB · price_targets + analyst_grades

Consensus target

$773.13

+39.19% upside

Low

$640.00

Median

$792.50

High

$830.00

Recent actions

0 ↑0 ↓8 hold

Apr 01, 2026
Mar 01, 2026
Feb 01, 2026
Jan 01, 2026
Dec 01, 2025

News

DB · news_items

Here's How IDEXX Laboratories Is Placed Ahead of Q1 Earnings
zacks.com·May 01, 2026

Recent quarters

All financials →

Period	Revenue	Net income	EPS
Q4 Dec 2025	$1.09B	$248.19M	$3.08
Q3 Sep 2025	$1.11B	$274.61M	$3.40
Q2 Jun 2025	$1.11B	$293.99M	$3.63
Q1 Mar 2025	$998.43M	$242.68M	$2.96
Q4 Dec 2024	$954.29M	$216.15M	$2.62
Q3 Sep 2024	$975.54M	$232.84M	$2.80

Recent insiders

All →

Insider	Action	Shares	Value	Date
Hunt Nimrata officer: Executive Vice President	Sell	1,758	$1.12M	Mar 03, 2026
MAZELSKY JONATHAN JAY director, officer: President and CEO	Sell	1,669	$1.09M	Feb 26, 2026
MAZELSKY JONATHAN JAY director, officer: President and CEO	Sell	1,000	$662.16K	Feb 26, 2026
MAZELSKY JONATHAN JAY director, officer: President and CEO	Sell	1,200	$793.32K	Feb 26, 2026
MAZELSKY JONATHAN JAY director, officer: President and CEO	Sell	1,343	$882.14K	Feb 26, 2026
MAZELSKY JONATHAN JAY director, officer: President and CEO	Sell	1,488	$975.9K	Feb 26, 2026

Income statement · annual

Open Financials →

Period	Revenue	Op income	Net income	EPS	Net margin
FY 2025	$4.3B	$1.36B	$1.06B	$13.08	+24.62%
FY 2024	$3.9B	$1.13B	$887.87M	$10.67	+22.78%
FY 2023	$3.66B	$1.1B	$845.04M	$10.06	+23.08%
FY 2022	$3.37B	$898.77M	$679.09M	$8.03	+20.17%
FY 2021	$3.22B	$932.03M	$744.85M	$8.60	+23.17%